This review summarizes the mitochondrial dysfunctions that drive glioma progression, highlights clinical trials and therapies aimed at mitochondrial targeting, and discusses emerging approaches such as caseinolytic protease P (ClpP) and disruption of mitochondrial–epigenetic interactions that may improve outcomes for patients with high-grade glioma. The gene discussed is CLPP; the disease is glioma.